biotech bellweth still strong
thousand oak fortifi biosimilar
initi coverag outperform target price
attract rel peer underappreci biosimilar
busi could help chang project base busi revenu
declin rel stabil vs large-cap peer vari promis
pipelin novel asset oncolog immunolog compel
valuat good balanc return capit sharehold
repurchas dividend pipelin abil yet urgent need
grow biosimilar busi could help return revenu growth
thesi grow biosimilar busi view anchor
next leg revenu growth even base busi declin see
potenti global gener sale view franchis
help mitig replac lost revenu current base busi
oncolog pipelin amgen novel oncolog pipelin price could
provid signific addit upsid clinic data readout harder
quantifi like broad oncolog platform asset address
high-valu target area unmet medic need updat oncolog
pipelin could provid sourc upsid catalyst near mid-term
price discount slow eros base busi well
known potenti repres current valuat current
trade price-to-earnings discount vs ep factset
estim major pharma peer merck
valuat risk target price deriv dcf use
wacc in-lin peer termin growth risk litig
intellectu properti clinic development regulatori market
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biotechnolog compani engag
discoveri develop manufactur market human
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum tvgr better
current assumpt base-busi greater
current forecast assum greater expect
growth biosimilar franchis slower expect
declin base busi also assum posit data
readout pipelin asset regulatori
approv abp kanjinti us abp abp
lower base busi sale poorer growth profil
biosimilar busi key pipelin asset assum
slower expect growth biosimilar franchis
regulatori headwind drug approv ip litig
scenario assum lose patent litig soliri
enbrel also assum neg data readout pipelin asset
 close
tabl content
guidanc consensu expect
eros commerci busi manag appreci
hill biosimilar busi could produc increment
revenu
aimovig first mover competit space
tezepelumab could competit novel asthma treatment physician
amgen renew focu oncolog enough take bite
holt view
cs peer relationship amgen
outperform rate target price share base
strong biosimilar franchis like replac lost revenu eros
current commerci busi long-term rel stabil vs large-cap peer
broad innov pipelin promis asset oncolog immunolog
compel valuat driven clear long-term commerci strategi
good balanc return capit sharehold repurchas dividend pipelin
abil yet urgent need pleas see industri report detail
larg cap biotech sector
strength stabil amgen
develop manufactur
commerci small molecul biolog drug across therapeut area especi
oncolog immunolog compani strength busi divers emerg
biosimilar franchis divers pipelin -- current base commerci busi
specif like novel hematology/ oncolog asset tezepelumab asthma
macroeconom condit deterior would best suit sector
weather storm view given strength stabil amgen long-term
revenu growth reliant price upsid rather larg biosimilar busi
could complimentari health care polici focus reduc cost drug
base busi recogn current base commerci
expect declin next year patent expir headwind hamper
enbrel sensipar erythropoiesis-stimul agent esa franchis think
declin base busi like repres current valuat base
busi estim slightli consensu think stock under-valued
howev believ biosimilar franchis combin new pipelin asset
like make revenu loss
biosimilar busi like becom major revenu driver
seven asset develop commerci
biosimilar franchiseinclud biosimilar humira herceptin avastin rituxan
soliri estim show could gener biosimilar sale
expect slightli ahead long-term guidanc
believ compani requir develop expertis
manufactur capac market access experi success commerci
asid biosimilar platform also highlight broad work novel target
oncolog look forward june updat bcma bite
multipl myeloma psma bite prostat cancer kra small
molecul solid tumor
attract valuat forward price-to-earnings basi current trade
discount major us pharma mean regeneron
vertex think investor overli concern declin
base busi fail fulli appreci biosimilar pipelin opportun
capac yet urgent need pipelin full
oncolog immunolog biosimilar capac transact
estim cash unlik other need
 core invest thesi howev think deal
rang within realm possibl
defin base commerci busi aranesp enbrel epogen neulasta nplate prolia sensipar/mimpara
vectibix xgeva also includ repatha kyproli blincyto parsabiv
price target price deriv dcf use wacc slightli
bloomberg wacc termin growth forecast cash flow
risk risk litig revenu result meet exceed expect
intellectu properti key patent deem invalid overturn us ou
author clinic development clinic trial may neg pipelin asset
may produc expect result regulatori fda ema may delay fail
approv investig product commerci sale
oncolog platform expect updat american societi clinic oncolog
june bcma bite multipl myeloma psma bite
prostat cancer small molecul kra inhibitor solid tumor
could begin regular updat across oncolog portfolio could help
drive share out-performance view bite bispecif t-cell engag
especi half-lif extend version could eventu compet novel cell
therapi car-t hematology-oncolog market evolv next
year one leader develop kra inhibitor previous
deem undrugg target given rel immatur data
current includ contribut early-stag oncolog pipelin
estim howev continu posit data articul path approv
could see multipl expans share
tezepelumab asthmapotenti disruptor asthma market ad
pipelin divers partner astrazeneca develop could
signific novel asthma biolog think compel phase data set
partner astrazeneca like phase success patient without eosinophil
phenotyp fda recent grant breakthrough therapi design asset
asthma proprietari asthma survey detail regeneron
report also support like profil tezepelumab less enthusiast
tezepelumab atop dermat given neg phase trial yet plan addit
trial indic announc call
rel strong start better-than-expect revenu ep much
base busi in-lin slightli ahead consensu expect indic
realist street view note aimovig miss like driven full
realiz discount inventori account insur reset still
earli day launch believ favor script trend despit
competit sensipar gener eros seem full swing two entrant
launch risk us oncolog remain focu growth anticip
multipl data updat expect annual meet european launch
biosimilar kanjinti amgevita earli day grow sequenti
near-term outlook short term expect share trade pipelin
updat oncolog biosimilar asthma support believ beatabl
consensu expect given size commerci busi quarterli progress
especi on-going launch aimovig even could also drive share
howev could see weak news on-going patent litig mylan
neg expans pipelin small mid-siz deal could also help move
multipl
long-term outlook long term think remain one stalwart
major biotechnolog compani broad pipelin remain driven innov
revenu base shift pipelin expect continu growth high-valu
therapeut come market also believ biosimilar strategi well align
view health polici name drug price longer term think
biosimilar becom increasingli import compon global healthcar system
credit suiss view amgen rel peer rel coverag univers
believ base busi declin pipelin remain strong
posit biosimilar opportun think much better posit
space vs biosimilar busi limit profit must
share via samsung joint ventur remain buyer strength
compani need acquir near-term revenu support multipl expans
think compani ampl capac transact could supplement work
oncolog immunolog even neurolog
guidanc consensu expect
top linew consensu expect outperform rate
predic beat consensu expect balanc rather
commerci pipelin updat would chang trajectori busi
support multipl expans end slightli consensu expect
also slightli non-gaap ep mainli slightli lower revenu
expect slightli higher tax assumpt
capac urgent need healthi cash balanc
signific capac acquir believ would take
addit debt beyond current factor remain project cash flow
compani could spend close transact view
still believ deal rang within realm possibl cash
flow forecast includ expect share repurchas dividend given compani
consist use return capit sharehold believ need
acquir unlik other construct pipelin growth
prospect provid biosimilar franchis deal could see
someth oncolog space note manag appear sensit
price indic recent deal oncolog appear expens
furthermor get sens compani would engag mega-merg akin
bristol myers/celgen anyth would like stick earlier-stag deal
bolster compani oncolog pipelin see figur analysi
amgen stock expens rel peer
stock trade multipl forward earn
slightli ahead gilead
discount vertex regeneron howev
compar pharma peer current
trade discount pharma amgen
deserv vertex growth multipl long-term set-up
biosimilar oncolog warrant higher multipl pharma
peer gilead larger problem reflect
rel expens forward earn basi
vs gilead declin base
busi trade in-lin large-cap peer
deserv higher valuat regeneron
vertex given poorer growth profil limit pipelin
discount warrant revenu
declin vs growth
trade slight premium gilead think trade least in-lin major pharma mean
median slight premium tp impli multipl estim non-gaap ep given
underappreci biosimilar busi upsid asthma broad novel oncolog pipelin current estim
agre trade modest discount given revenu growth believ current discount great
ii evolut revenu base
eros base busi well appreci street
consensu estim compound-annual-growth-rate
expect biosimilar busi aimovig novel
oncolog pipelin fulli reflect estim fulli
factor would demonstr healthi shift base
busi even tezepelumab could meaning driver
help diversifi revenu base
eros shift revenu fairli reflect current
share price pe multipl
eros base busi underappreci street
consensu model stronger headwind affect enbrel
aranesp sensipar launch aimovig also
strong expect given competit contract
success
commerci even biosimilar tezepelumab asset
oncolog pipelin eros commerci busi
acceler faster expect neg affect amgn
share price compress pe multipl
unabl
forecast similar declin base busi vs consensu credit suiss compound-annual-growth-rate expect headwind across
key franchis enbrel biosimilar competit aranesp competit long- short-act asset
sensipar gener howev think upsid emerg biosimilar busi could make revenu
declin base busi layer potenti revenu aimovig even broader pipelin posit well
revenu growth think biosimilar franchis underappreci street fulli factor
upsid potenti pipelin
could see upward revis multipl pipelin
success play notabl novel hematolog asset
tezepelumab asthma posit data
key asset includ omecamtiv mecarbil small
across pipelin could help reliev pressur current
lack pipelin success like weigh share
replac revenu growth declin pipelin becom
increasingli difficult import asset
heme-onc tezepelumab succeed later-stag clinic
trial pipelin failur continu compress multipl
stock begin trade discount biotech pharma
think broad pipelin could address high-valu target notabl believ tezepelumab could differenti
asthma potenti challeng dupix novel biolog space given compel data expect data
updat june think strength novel oncolog pipelin could becom evid investor also
like focu bispecif diversif heme-onc addit car-t asset follow interest pre-
clinic kra inhibitor data look forward first clinic data dose escal trial
patient solid tumor could first-to-market kras-target therapeut therapeut target previous thought
undrugg later-stag clinic data emerg believ pipelin could drive re-rat share drive rel
perform vs peer broader market
resubmit fda
upheld court
data ad
launch eu
fda-approv
immun
settlement
figur amgen stock perform vs xbi ibb
charl martineau univers toronto figur credit suiss review amgen pipelin asset
metastat colorect breast
model
solid tumor kra mutat phase clinic data
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase clinic data asco
phase start
judg decis court case vs sandoz
district court decis praluent patent
abp biosimilar infliximab
kanjinti biosimilar trastuzumab
abp biosimilar rituximab
target price amgen deriv dcf analysi use
wacc in-lin large-cap biotech peer termin valu growth rate
project fulli dilut share flow repres figur
base case experienc commerci regulatori organ
support diversifi portfolio product domest intern market
believ broad portfolio track record execut lower risk
achiev forecast incorpor view model via discount
forecast cash flow account known expect product launch
patent expir competit threat current commerci portfolio
pipelin beyond forecast period appli termin growth rate termin cash
flow believ eros base busi off-set growth
elsewher portfolio continu invest bd
success replac revenu rate eros long-term
contribut biosimilar investig oncolog asset tezepelumab base
case dcf valuat per share repres approxim upsid
recent close price see figur sensit analysi impli narrow
band valuat per share varieti reason termin growth
charl martineau univers toronto figur amgen dcf analysisbas
increas /decreas wc
dilut share current price
valuat depend part perform base busi
revenu perform sensit analysi assess impact
valuat varieti scenario see figur believ rate eros
base busi well understood investor openli discuss
compani sensit analysi suggest even bear case
busi miss expect would still trade discount fair valu
figur dcf sensit tvgr
success tvgr varianc
revenu adj base busi
valuat scenario assum termin valu
growth rate vs current base busi greater
current forecast assum greater-than-expect growth biosimilar
franchis slower-than-expect declin base busi also assum
posit data readout pipelin asset regulatori approv
abp kanjinti us abp abp furthermor assum commerci
launch amjevita us scenario assum win ip litig
enbrel soliri
grey valuat grey scenario assum poorer termin
valu growth rate lower base busi sale poorer growth profil
biosimilar busi key pipelin asset assum slower-than-expect
growth biosimilar franchis regulatori headwind drug approv ip
litig scenario assum lose patent litig soliri enbrel
also assum neg data readout pipelin asset
litig on-going litig vs sandoz concern enbrel ip
protect asset late decis expect near term
sandoz prevail biosimilar enbrel could launch earlier expect
could depress sale patent case defend enbrel
ariad pharmaceut coheru bioscienc
held sandoz bring approv enbrel biosimilar market
past sever year note introduct biosimilar would
immedi mean revenu cliff could mean faster price eros market
share loss enbrel sale
commerci risk revenu gener base commerci busi
drive major revenu earn estim sale wors
consensu expect could see share pressur
intellectu properti ip risk much success reliant strong
patent protect ip gener biosimilar manufactur success
challeng key patent signific portion compani
revenu base may risk loss major patent either us ou
could hurt share price inabl challeng ip innov product
could hamper growth biosimilar busi
clinic develop risk valuat share upsid
potenti base outcom clinic trial late-stag
asset shown clinic ineffect unsaf would expect neg
pressur share
regulatori risk food drug administr fda european medicin
agenc ema regulatori bodi approv requir
market sell therapeut delay outright reject approv
investig asset could neg impact futur cash flow
valu share furthermor fda ema could revok
market author market product due safeti efficaci
concern demonstr post-market set
external/market risk biotechnolog remain volatil sector
affect extern factor includ drug price legisl intellectu properti
law healthcar polici overal economi neg polici develop
and/or weaken economi could affect share price
eros commerci busi
manag appreci consensu
believ eros base commerci busi exclud aimovig
manag well appreci consensu estim upsid
biosimilar busi lesser extent even tezepelumab pipelin
asset enough view replac revenu declin contribut
revenu growth think invest oncolog novel bispecif review later
report help remain relev end see declin base
busi natur evolut compani matur loss exclus
loe product figur show pipelin asset could chang growth
trajectori revenu
broadli defin base busi follow product aranesp enbrel epogen
neulasta nplate prolia sensipar/mimpara vectibix xgeva also
includ recent approv product repatha kyproli blincyto parsabiv
review key asset provid individu outlook help demonstr near-term
everyth base busi expect face patent cliff sale quickli
erod asset real durabl could help provid
repathalik winner commerci battl
repatha becom import driver base busi less risk
posit litig rule launch challeng
recent seen revers trend script pick repatha drug
experienc signific growth total prescript see figur
project larger growth repatha
vs consensu see figur expect gap end-us
sale widen repatha vs praluent given current trend furthermor note
repatha cvot outcom data one year ahead regeneron/sanofi enabl
updat pi detail physician sooner forecast signific differ
total sale repatha praluent model
juri upheld valid two patent relat
antibodi addit similar attempt sanofi invalid patent repatha
fail japan europ patent case regeneron sanofi
go year final resolut could see settlement two
parti exclud possibl amgen regeneron model total
injunct praluent would boon expect given prior
argument court suggest remov praluent market could hurt
public think back forth remain nois without materi impact
even regeneron/sanofi requir pay royalti might amount
annual would materi
expand access driven repatha list price reduct amgen
announc octob would lower repatha list price
move arguabl motiv sanofi regeneron price cut
praluent list march also help open access medicar patient
lower list price vs higher rebat reduc out-of-pocket cost medicar part
beneficiari note abandon rate medicar patient
afford issu lower price would reportedli reduc out-of-pocket monthli
cost accord medicar patient account
repatha base compani expect share increas ident
higher-pr sku remain market next sever year allow
smoother transit healthcar plan includ lower-pr sku expect
see greater effect lower list price announc last year came
healthcar plan pharmaci benefit manag pbm negoti
formulari would expect plan updat new list price
signific price reduct believ abl increas
patient number maintain medicar popul drive upsid
enbrelstil project gener per year year
signific headwind ahead like produc steadi market eros prior
therapi patent litig pose threat enbrel factor gener well
appreci enbrel expect declin annual basi openli discuss
factor believ well appreci consensu enbrel
unknown close watch on-going litig vs sandoz could
get decis near term sandoz prevail could see biosimilar enbrel
sooner could depress sale note introduct biosimilar
immedi mean revenu cliff jnj remicad held sale could
recent report sale declin due volum net sell price declin
continu expect price compress remain competit crowd
anti-inflammatori market biosimilar threat eventu expect although patent
litig on-going discuss later like determin time competit
expect novel therapi jak inhibitor addit biolog
headwind exclud patent litig repres smaller addit effect togeth
pose seriou risk enbrel sale therefor expect sale declin steadi rate
compound-annual-growth-rate year lead patent cliff
enbrel unknownu patent litig vs sandoz enbrel biosimilar current
await final verdict amgen await district court verdict close
argument made novemb regard sandoz biosimilar erelzi fda
approv un-market infring enbrel patent note
lost patent rule march seek invalid enbrel patent
highlight event lose file appeal request temporari
injunct biosimilar
key litig event highlight
amgen immunex corpor amgen manufactur roch
file lawsuit district court new jersey sandoz infring
patent
fda approv sandoz erelzi biosimilar enbrel
new jersey court held bench trial hear argument
regard sandoz challeng patent
close argument present parti
two patent cover composit matter enbrel protein
expir henc posit verdict could help secur
exclus anoth year
overal enbrel remain driver base busi although steadi
declin expect enbrel experienc compound-annual-growth-rate world-wide ww
drug account sale expect price
market competit erod market share compound-annual-growth-rate patent
expir patent litig also pose signific risk sale could
permit biosimilar entri prior patent expir project sale declin
gener in-lin consensu expect see figur
prolia even
amgen osteoporosi franchis like continu help drive base
busi expect prolia grow compound-annual-growth-rate in-lin consensu toward
see figur forecast smaller growth prolia approach patent
expir us eu upon expir expect signific
reduct sale potenti gener competit believ even romosozumab
complementari drug prolia repres signific growth opportun
osteoporosi franchis project world-wide ww end-us sale
see figur note partner ucb even wherea
book us sale ucb book outsid us ou sale forecast profit share
arrang model
even could sourc upsid compar forteo teriparatid anoth
osteoporosi drug sale last year forteo black box warn
osteosarcoma even one cardiovascular risk despit warn forteo
manag signific revenu even compar wors side effect
believ even like outperform consensu expect despit warn sinc
cardiovascular cv side effect frame studi less meaning
origin thought view street appreci complementari natur
even prolia see even sale cannib prolia
complementari approach differ target drug intend treat
postmenopaus women high risk fractur prolia monoclon antibodi mab
inhibit receptor activ rankl nuclear factor kappa-b ligand even activ
rankl bind rank osteoclast increas bone breakdown resorpt bone
back bloodstream even also mab block sclerostin see figur
inhibitor osteoblast cell help build bone drug posit effect mitig
osteoporosi even work directli promot osteoblast bone-build activ
prolia work limit osteoclast bone-breakdown activ mechan drug
complementari even indirect activ decreas bone resorpt sclerostin
upregul rankl therefor overlap prolia
even larg treatabl popul despit black warn even
earli stumbl drug approv fda advisori committe vote ye approv
member approv januari concern safeti cardiovascular
side effect phase trial recent fda approv includ
black box warn patient prior myocardi infarct stroke within
preced year warn could limit drug popul believ
overal effect modest larg subpopul still elig even
requir complet post-market studi assess potenti cv effect may
get better understand larger studi complet
neulasta
biosimilar affect g-csf franchis increas competit granulocyt
coloni stimul factor g-csf franchis significantli erod market share neulasta
sale slowli declin compar due recent patent
expir us eu biosimilar competit us biosimilar
fulphila coheru udenyca neulasta approv competitor
launch europ
signific market eros expect year project
compound-annual-growth-rate neulasta vs see figur
ask think eros g-csf asset state
experi plan suggest typic everi case differ sort
averag year innov might half market
project slightli slower declin reduct three year believ amgen
retain greater market share due onpro devic on-bodi injector
conveni deliv drug could modest driver help hold onto
greater market share regard would expect continu declin first-
gener drug although slower rate neulasta first-gener g-
csf neulasta pegyl version intend stay activ longer neupogen
sale repres one-third unit share short-act market
sensipar/mimpara parsabiv
sensipar litig recent resolv teva begin sell gener sensipar
januari teva settl long-standing disput
sensipar ip teva agre stop sell compani approv gener version pay
undisclos amount project sale declin significantli due
revenu parsabiv reflect model addit state
lower owe higher purchas due reimburs chang
part project compound-annual-growth-rate vs consensu increas
declin due gener entri teva see figur
high uptak expect parsabiv compound-annual-growth-rate strong uptak parsabiv
launch independ mid-siz dialysi provid produc
project stronger growth larg dialysi organ increas adopt
parsabiv expect larger center main sourc revenu model
compound-annual-growth-rate vs consensu stronger uptak short term
parsabiv take market share sensipar see figur
car-t/bispecif like impact kyproli sale outer year
compound-annual-growth-rate given highli competit crowd space project overal
declin growth kyproli carfilzomib proteasom inhibitor use second-
third-lin multipl myeloma drug experienc slow growth
estim compound-annual-growth-rate slightli lower
consensu rate see figur model consensu
take account competit novel car-t bispecif enter
space expect declin growth toward patent expir exclud patent
term extens note gener revlimid materi impact kyproli
revlimid use first line use combin kyproli
epogen aranesp
esa franchis continu declin biosimilar threat erythropoiesis-
stimul agent esa epogen aranesp declin yoy
respect driven
lower net sell price biosimilar competit price
compress expect increas epogen per guidanc therefor
model compound-annual-growth-rate epogen see figur newli approv
short-act biosimilar retacrit penetr market retacrit first
biosimilar esa avail us feel retacrit discount epogen upon
approv caus seriou disrupt short-act esa market afford
patient import driver space attempt switch patient
small mid-siz dialysi center aranesp slow eros esa sale note
short-act esa commonli use dialysi patient sinc requir
multipl inject per week henc typic given dialysi
project slower signific declin aranesp vs epogen
compound-annual-growth-rate vs consensu patent expir see figur long-
act esa aranesp includ epogen competit vifor pharma/roch
mircera aranesp compet directli aranesp us nephrolog segment
janssen/johnson johnson procrit compet directli aranesp us support
care pre-dialysis set view price pressur dialysi center produc
faster aranesp declin current appreci eu repres nearli
half aranesp sale flat growth yoy see figur would expect
continu market eros nephrolog segment eu multipl epoetin alfa
biosimilar market us aranesp revenu declin yoy due
competit project greater declin vs eu sale due market eros nephrolog
segment nephrolog set repres much greater share us revenu vs eu
figur breakdown esa franchis revenu
produc increment revenu
current base busi declin think amgen emerg
biosimilar busi could revenu driver analysi
biosimilar busi becom signific driver commerci busi
ip expir transpar around patent disput threat
biosimilar affect part base busi biosimilar could one
answer revenu declin
biosimilar franchis provid grow long-term flow
help replac matur brand face competit view well-suit
execut base strong experi develop commerci
biolog combin success patent litig addit compani
divers product line could support extend time-to-market delay litig
flexibl offer competit discount increas payer coverag
tailwind biosimilar busi includ
grow market biolog evid origin sale
 anti-tnf leverag multipl indic
potenti first line statu
believ amgen strategi invest biosimilar also make sens macro
level biosimilar potenti sustain less sensit price
legisl featur import healthcar industri move toward
biosimilar could drive signific upsid amgen like take share
market develop biosimilar compet market share brand
drug account origin product sale compani six
late-stag biosimilar drug either approv develop see figur six
biosimilar repres potenti market addit early-stag
biosimilar develop repres market point see
near-term opportun europ eu sale vs us due histor
friendlier environ biosimilar approv greater clariti patent disput
howev imbal geograph market share even us patent
overhang resolv model eu share biosimilar
sale mainli driven growth amjevita us potenti sale septemb
settlement grant amjevita biosimilar humira patent licens
begin sell drug
given strength broad biosimilar portfolio think long-term sale
exceed gener guidanc compani provid potenti
biosimilar alreadi market europ includ amjevita kanjinti
biosimilar herceptin receiv approv eu us mvasi
biosimilar avastin expect potenti launch regulatori file
eu us recent complet abp biosimilar remicad expect
potenti bsufa approv commerci launch like follow
complet phase trial januari evalu abp biosimilar rituxan
mild-to-moder rheumatoid arthriti trial met primari endpoint current
anoth abp phase trial non-hodgkin lymphoma on-going expect
conclud conserv estim launch abp account
data analysis/prepar bla submiss six-month approv process
abp amgen biosimilar eculizumabposs way captur
alexion pnh ahu busi develop biosimilar orphan
indic pose differ challeng vs larger indic ra psoriasi
signal point commit potenti biosimilar eculizumab
recent file ipr challeng three recent grant us patent soliri cover
composit matter formul method treatment pnh suggest
compani plan eventu pursu regulatori approv biosimilar
eculizumab even alexion abl convert patient ultomiri could
opportun lower-pr altern european countri typic
open biosimilar competit current estim biosimilar eculizumab
could launch europ patent issu us biosimilar
like unless ipr success
compani data credit suiss estim patent licens begin ra trial complet on-going non-
hodgkin estimate complet alexion lost eu patent litig extend patent
compound-annual-growth-rate commerci busi estim increment upsid
biosimilar could convert commerci busi declin compound-annual-growth-rate
increas see figur sever base busi drug experi
patent expir next five six year includ aranesp nplate prolia vectibix
xgeva drug enbrel undergo litig could threaten
exclus furthermor biosimilar competit creat headwind amgen
commerci busi neulasta sensipar believ
addit valu biosimilar franchis import maintain profit
addit upsid pipelin would add potenti upsid share price
figur biosimilar could add compound-annual-growth-rate exist base busi
biosimilar help drive revenu growth erod legaci base
busi amjevita mvasi sale boost franchis model biosimilar
grow compound-annual-growth-rate vs consensu driven better-than-expect growth
amjevita biosimilar adalimumab follow settlement allow us entri
earli also forecast greater sale biosimilar owe increas
confid compani abil commerci asset versu competitor
model humira repres largest share biosimilar market henc
project biosimilar sale come amjevita also project equal
contribut kanjinti/herceptin biosimilar abp biosimilar abp
biosimilar mvasi/avastin biosimilar abp biosimilar
repres sale due smaller market uncertainli around ip
face eros base busi particularli enbrel howev
believ biosimilar franchis provid signific cash flow support matur base
busi support pipelin
figur bullish biosimilarscredit suiss vs consensu
model biosimilar use histor sale drug origin
start point forecast volum growth base popul rate expect
biosimilar take percentag origin sale year increas market
penetr percentag increas significantli patent origin drug
expir growth slow market matur forecast price discount
origin market model kanjinti herceptin abp remicad amjevita
humira abp rituxan abp soliri detail figur
figur forecast probabl success po unapprov biosimilar
model higher po phase asset phase trial need prove
biosimilar candid non-inferior origin figur contain summari sale
forecast biosimilar
competit advantag develop manufactur varieti biolog
asset view strong track record develop drug win
regulatori approv success commerci
manufactur compani commerci asset intern pipelin
develop late-stag asset acquir highlight leader
manufactur biolog critic compon success commerci
biosimilar addit elig full econom sale biosimilar
unlik competitor must share sale jv partner samsung
histori success litig ip iron abl limit competitor
seek enter market prior patent expir due compani skill litig ip
note compani patent case defend enbrel ariad
held sandoz
bring approv enbrel biosimilar market past sever year current
wait verdict furthermor court recent upheld two patent repatha
sanofi praluent biosimilar front note also settl
humira allow compani commerci amjevita us amgen
success win patent case give us greater convict navig complex ip
landscap requir success commerci biosimilar asset
bundl tactic innov molecul manufactur stymi growth
biosimilar like subsid year point on-going
litig janssen/ regard potenti anti-competit contract
janssen essenti prevent payer provid offer lower-cost
biosimilar remicad argu janssen/jnj engag contract tie
rebat janssen product inclus remicad exclus biosimilar
provid opt lower-cost biosimilar janssen rebat risk
would put provid financi risk asid highlight issu
current rebat system us also highlight potenti tactic innov
use prevent competit entri biosimilar august us district court
eastern district pennsylvania deni jnj motion dismiss anti-trust civil
lawsuit brought remicad contract watch case close
better understand emerg legal think around rebat contract
competit tactic exclud biosimilar sale
fda also address issu anem biosimilar competit juli
action plan link fda document subsequ comment former fda
commission scott gottlieb biosimilar uptak identifi slow due
rebat program bundl gottlieb state growth biosimilar
anem consolid across suppli chain made
attract manufactur pharmaci benefit manag group purchas
organ distributor
volume-bas rebat refer biologicsor bundl biolog
productsrath embrac biosimilar competit lower price
patent thicket essenti biolog protect hundr
patent delay biosimilar entri year product protect
multipl decad post initi launch
split monopoli profit
note fda identifi clear problem protect innov
biolog agenc offer concret plan beyond support market competit
reduc game fda requir attempt unfairli delay market
competit follow-on product
kanjinti biosimilar herceptin trastuzumab
abp biosimilar remicad infliximab
amgevita/ amjevita biosimilar humira adalimumab
abp biosimilar rituxan rituximab
abp biosimilar soliri eculizumab
mvasi biosimilar avastin bevacizumab
kanjinti biosimilar herceptin trastuzumab
kanjinti share origin sale
kanjinti discount origin
kanjinti share origin sale
kanjinti discount origin
abp biosimilar remicad infliximab
abp share origin sale
abp discount origin
abp share origin sale
abp discount origin
amgevita/ amjevita biosimilar humira adalimumab
amgevita share origin sale
amgevita discount origin
amjevita share origin sale
amjevita discount origin
abp biosimilar rituxan rituximab
abp share origin sale
abp discount origin
abp share origin sale
abp discount origin
abp biosimilar soliri eculizumab
abp share origin sale
abp discount origin
abp share origin sale
abp discount origin
mvasi biosimilar avastin bevacizumab
mvasi share origin sale
mvasi discount origin
mvasi share origin sale
mvasi discount origin
aimovig first mover competit space
first-to-market advantag increas competit pose signific headwind
novel migrain therapeut aimovig first fda-approv drug
anti-cgrp class one year sinc launch revenu growth
upsid asset remain mute enjoy first-mov advantag seen
new total prescript growth figur competit begun erod
advantag recent approv launch teva lilli commentari
compani result reinforc aimovig remain market leader class
convert script revenu challeng commerci coverag remain around
cover live patient still receiv free drug think effect
contract secur prefer formulari access like key factor determin
win market sale upsid aimovig core thesi would
still like see continu progress convers patient reimburs therapi
despit headwind believ aimovig remain domin player
near term could import driver compani revenu note
benefit includ widespread payer coverag load dose lower
head start may wane aimovig first fda-approv may calcitonin
gene-rel peptid cgrp inhibitor stiff competit ajovi teva
emgal lilli like captur market share product
launch phase approv septemb first-to-market bump aimovig
saw total prescript ajovi emgal
drug sixth month market howev aimovig start face headwind look
nrx see figur see figur trend note aimovig
stronger launch start see consist declin nrx
expect addit competit injectable/iv market alder eptinezumab
furthermor oral formul allergan biohaven develop
could increas competit expect migrain market get competit
new market entrant rel undifferenti data approv cgrp
inhibitor brand prefer like determin combin payer dynam
dose conveni better side effect profil even strong initi launch see
aimovig lose market share competitor howev think consensu could
account crowd market slightli ahead consensu
expect believ aimovig posit first-to-market last effect
penetr rel competitor
market leader slower growth vs competitor project revenu
us sale less royalti novarti plu royalti receiv novarti eu
sale deriv less royalti paid novarti end-us
sale us outsid us royalti receiv novarti see
figur compound-annual-growth-rate estim ahead consensu forecast
note consensu forecast stronger growth emgal
compound-annual-growth-rate ajovi compound-annual-growth-rate aimovig enjoy first-to-market
benefit give compani head start negoti better payer formulari coverag
discuss later detail howev nrx aimovig level
opportun smaller prior competitor entri agre consensu
emgal aimovig two main near-term player space ajovi like
come third mainli due less payer coverag overal market share drug
expect decreas new entrant oral dose becom avail
account market model
figur project revenu cgrp inhibitorscredit suiss vs consensu
gain clear competit edg cgrp difficult multipl player
aimovig continu face market eros emgal ajovi fourth player
alder eptinezumab current review fda pdufa
eptinezumab show slight advantag chronic set discuss later howev
uncertain would make commerci differ eptinezumab potenti fourth
market difficult erod progress made approv cgrp
nevertheless potenti room addit player alder could gain
oral cgrp migrain prophylaxi chronic set could also competit
threat like sever year away ad competit mix oral therapi
could enter market earli allergan ubrogep current fda
review pdufa date biohaven plan file nda rimegep zydi
oral dissolv tablet rimegep grant prioriti review fda
therebi set potenti approv end howev drug seek
approv acut set near term oral drug would like smaller
effect inject market chronic migrain oral drug studi
chronic migrain unknown efficaci would chronic migrain
prevent third gener oral cgrp chronic episod migrain prevent
develop atogep allergan studi prevent set episod
migrain also highlight definit sever episod migrain chronic
migrain vari similar margin headach day seem
boundari two distinct
payer coverag potenti biggest factor brand adopt aimovig
emgal greatest coverag emgal widest coverag three
approv cgrp inhibitor list prefer formulari express script
optumrx figur aimovig prefer express script optumrx
exclud ajovi least cover drug prefer
non-pref express script optumrx prefer coverag like driven
price discount payer recent reuter articl link articl suggest teva
less will discount ajovi contract discuss confidenti
think lilli like will give larger discount rebat
payer still teva state earn compani happi current coverag
commerci sector contract vari year year think
unlik see signific chang coverag landscap near term
factor play could help aimovig emgal get wider coverag
strong us presenc relationship payer addit aimovig initi
advantag first market four five month could see payer
dynam chang market becom competit drug maker like
increas discount gain maintain coverag
figur formulari coverag fda-approv migrain therapi
pbm
clinic data rel undifferenti among inject therapi winner
trial data alon clinic data figur highlight pivot trial three approv
cgrp inhibitor eptinezumab fda review episod em chronic migrain
cm look efficaci chang migrain headach days/month obviou
differ four drug emgal appear perform better vs placebo em
dose days/month reduct aimovig show similar efficaci em highest
dose days/month eptinezumab aimovig look good higher dose cm group
number differ drug note head-to-head trial data
exist therefor draw definit comparison drug essenti efficaci
side effect appear rel similar channel check physician confirm
current agent perceiv similar differ ajovi eptinezumab approv
less frequent dose could provid greater conveni
figur trial data inject cgrp inhibitor
chang
product detail could smaller role brand adopt aimovig
load dose better deliveri system lowest inject reaction
conveni comfort may factor brand prefer prefer drug
formulari aimovig emgal conveni deliveri system
autoinjector/pre-fil pen compar ajovi pre-fil syring see figur
autoinjector shown improv complianc success self-administr
stauffer et al addit ajovi syring suggest reason
higher inject site reaction vs aimovig emgal initi
load dose first month emgal small possibl signific disadvantag
aimovig
figur comparison aimovig emgal ajovi prescrib inform
month
month patient
month
month
label
label
abdomen thigh outer area
upper arm
abdomen thigh back
upper arm buttock
abdomen thigh back
upper arm
though depth inject
locat
type needl
size needl
cgrp signific breakthrough migrain treatment drug select base
payer coverag accord neurologist channel check neurologist highlight
posit sentiment toward cgrp believ cgrp signific breakthrough
migrain treatment patient see signific improv overal
see posit effect physician see pattern regard efficaci among
three inject drug clear differ efficaci interestingli state
respons specif cgrp patient-specif failur one cgrp
preclud failur anoth therefor commonli switch anoth cgrp
respons observ importantli comment payer coverag avail still
major factor drive drug select
aimovig greatest market visibl channel check auto-injector
differenti constip could caus switch accord channel check
neurologist aimovig market visibl greater referr state
patient ask aimovig name howev constip issu
patient may prompt use altern patient suscept
histori constip auto-injector use aimovig emgal
potenti differenti due less pain inject compar ajovi teva
reportedli develop auto-injector
aimovig econom novarti enter agreement novarti april
jointli develop commerci aimovig book us sale
novarti book ex-u sale share commerci cost total sale
compani recogn novarti fund portion global expens addit
compani due double-digit royalti net sale product book partner
estim royalti compani model furthermor novarti
pay certain commerci expenditur mileston achiev
see figur us ou cgrp market model
patient million
patient fail botox
chronic patient elig aimovig
patient unrespons triptan therapi
patient elig aimovig
patient treat round
aimovig erenumab royalti novarti market
unadjust gross sale book excl cog
royalti paid novarti
unadjust net sale book excl cog
patient million
popul million
patient fail botox
chronic patient elig aimovig
patient unrespons triptan therapi
patient elig aimovig
patient treat round
discount us list price
aimovig erenumab novarti royalti paid
unadjust sale book novarti
royalti paid excl cog
tezepelumab could competit novel asthma
novel biolog space asthma
tezepelumab could differenti given efficaci seen phase trial
potenti increment end-us sale view asthma
opportun provid interest option share begin
potenti pivot data tezepelumab could provid addit multipl turn
share beyond upsid biosimilar novel oncolog franchis
phase trial saw compel efficaci data especi compar
biolog space includ regeneron/ sanofi dupix see figur think
mechan target tslp thymic stromal lymphopoietin differenti
phase trial demonstr efficaci patient regardless baselin eosinophil
count physician survey asthma prescrib rel high interest
asset despit recent enter phase clinic trial also note fda
patient without
eosinophil phenotyp indic agenc like interest potenti
use popul howev model modest growth expect dupix
maintain lion share market safe drug first-mov advantag
figur efficaci comparison across novel asthma therapeut approv investig
reduct
black box risk anaphylaxi administ
hc set prepar manag anaphylaxi
observ patient appropri period time
administr
black box risk anaphylaxi administ hc
set healthcar profession prepar
sc formul ciqair
reconstitut administ healthcar
profession monitor patient
administr biolog agent recommend
administ hc profession
monitor patient administr biolog
agent recommend
pivot trial demonstr reduct overal popul
reduct high eosinophil popul eos/ml
approv septemb add-on therapi
patient eosinophil phenotyp
 reduct among differ dose cohort similar result
observ patient regardless blood eosinophil count enrol
take share if/when launch around conserv estim could
forecast peak unadjust end-us sale
project revenu profit share in-lin consensu see
figur also highlight co-develop asset astrazeneca
two compani spilt develop cost start receiv mid-
single-digit royalti profit loss split equal note agreement
could updat allow drive commerci highlight
astrazeneca alreadi asthma-focus field forc sale fasenra
charl martineau univers toronto figur tezepelumab ww revenu profit share credit suiss vs
consensu estim go
tezepelumab could gain greater share among type patient
uncontrol oral inhal therapi note editori new england
journal medicin accompani trial public link full public
conclus tezepelumab appear broadest promis
biolog treatment persist uncontrol asthma date reduc
asthma exacerb rate half improv lung function irrespect
asthma phenotyp elisabeth bel ph septemb link editori
upstream natur tslp could help explain asset appear work
eosinophil non-eosinophil phenotyp diseas also note
drug substanti posit effect two import marker inflamm
asthma name blood eosinophil count fraction exhal nitric oxid feno
bel indic biolog asthma effect
biomark see strong efficaci examin exacerb reduct
improv bronchodil see figur
annual wk
fev bronchodil
patient evalu
baselin wk
baselin wk liter
patient evalu
baselin wk
patient evalu
baselin wk
signal seen phase wait phase data full
confirm safeti profil benefit target upstream cytokin
seen clinic efficaci author editori data note possibl increas
infect risk tslp affect dendrit cell cell innat immun cell
look summari phase note saw higher rate
seriou event placebo arm vs activ arm
howev see slightli higher rate nasopharyng tezepelumab-tr arm
vs placebo like driven low-dos arm see figur
phase summari
event grade
seriou event
event lead
discont trial
common event grade
proprietari survey asthma prescrib indic interest phase data
tezepelumab main result overwhelmingli support dupix
view efficaci approv product trend
support notabl respond prefer therapeut
work patient regardless blood eosinophil count fit profil
tezepelumab see figur review clinic data respond rank phase
tezepelumab data second first dupix phase trial suggest
higher enthusiasm asset among prescrib physician see figur
assess rel safeti profil tezepelumab less conclus see figur
think question regard potenti increas risk infect need
address phase program addit data trial
physician like becom comfort profil
figur degre agreement statement prefer
current satisfi
avail option treat
patient uncontrol
prefer therapeut work
patient regardless
prefer therapeut
administ home
 neither agre
survey background better assess current state moderate-to-sever asthma market us conduct
survey intern medicin physician specialti allergy/immunolog pulmonolog select physician
current practic us varieti treatment set privat practic community-bas practic
academic/teach non-academ hospit respond report see moderate-to-
sever asthma patient per month averag mean patient patient cover survey physician
indic privat insur cover medicar cover medicaid
figur compel therapi review
therapeut dose efficaci data
figur compel therapi review
safeti advers event data
respond
respond
formal model
amgen renew focu oncolog enough
take bite competit
address high-valu target
investig oncolog asset believ investor focu develop
across pipelin next year see figur success asset
potenti drive share upsid could meaning contribut
evolut commerci busi estim success one two
bispecif brand bitesbispecif t-cell engag could easili
gener increment sale per asset like approach address
hematolog malign platform compani coverag
take car-t approach clinic success bite could less costli faster
option address diseas multipl myeloma mm acut myeloid leukemia
aml given myriad constraint autolog car-t therapi seen
anem sale kymriah yescarta believ opportun bi-specif
heme-onc beyond bite also pursu cell therapi small
molecul hematolog malign emphas either-or
got initi efficaci data bite target bcma
mm bite target aml hint efficaci acknowledg
limit asset need continu infus thu look
forward data hle half-lif extens version asset could
address issu addit excit potenti small
molecul target kra tradit undrugg target solid
tumor close watch novel oncolog pipelin
increment data possibl chicago illinoi may june later
year orlando florida decemb
figur upcom amgen present
phase studi evalu safeti toler pharmacokinet pk efficaci
novel small molecul inhibitor advanc solid tumor
evalu anti-bcma bispecif t-cell engag bite immunotherapi r/r multipl
myeloma mm patient updat result first-in-human fih phase dose escal studi
nonclin safeti assess investig car-t therapi
phase studi half-lif extend bispecif cell engag bite antibodi construct
target patient small cell lung cancer sclc
phase studi chimer antigen receptor cell therapi target
patient relapsed/refractori small cell lung cancer sclc
novel anti-egfrviii bispecif cell engag bite antibodi construct glioblastoma gbm trial
progress patient recurr newli diagnos diseas
inhibitor radiat therapi treat patient soft tissu sarcoma wild-
phase ii trial carfilzomib irinotecan relaps small cell lung cancer
efficaci carfilzomib lenalidomid dexamethason krd without transplant newli
diagnos myeloma accord risk statu result fort trial
safeti efficaci once-weekli carfilzomib dose frail patient pt subgroup analysi
phase studi
carfilzomib relaps refractori multipl myeloma rrmm frailti subgroup analysi
phase endeavor
weekli mg/m carfilzomib lenalidomid dexamethason progress earli relaps
view littl credit like given specif program suggest
posit risk/reward asset note need achiev
approv commerci success asset support long-term
relapsed/refractori multipl
first asset interest mm target bcma
sick patient see figur saw hint efficaci encourag orr
mid-high dose cohort mcg/d gener follow dose-depend
respons figur see higher dose blue star mcg/d purpl
circl display greater decreas baselin measur serum immunoglobulin-
free light chain flc measur monitor therapi success multipl myeloma
lower level flc would indic greater diseas resolut furthermor lower dose
yellow squar mcg/d orang circl demonstr increas
flc baselin gener appear green triangl mcg/d
group follow consist pattern suggest appropri dose may lie
somewher rang discuss earlier mcg/d well toler due
dose-limit toxic group show decreas flc baselin although less
data avail assum treatment stop earli
patient show respons data promis particularli
pre-treat popul mcg/d group show consist
result see figur four five patient demonstr minim residu diseas
neg stringent complet respons mrdneg scr best rate mrd-neg
patient less like experi diseas relaps furthermor scr stricter rate
sinc includ complet respons cr paramet requir normal flc ratio
without clonal plasma cell bone marrow overal object respons rate
orr mcg/d group
highlight posit result trial popul number respond
small therefor difficult draw conclus gener popul one
outstand question long-term durabl therapi mcg/d group
show reason durabl long-term data avail sinc trial still
on-going also note work determin dose phase
charl martineau univers toronto potenti pivot trial on-going phase trial see link optimist
promis data remain cautiou consist data present
also close watch data hle version molecul
figur kinet tumor responsefollow
star
month
highlight advanc diseas trial popul one-third
patient prior stem cell transplant patient previous treat mani
time median four prior line therapi see figur popul clearli
advanc could contribut increas number infect
observ sick popul feel posit efficaci data assum
safe would point promis platform oncolog space
prior line therapi median rang
plasma cell baselin median rang
reason safeti confin mcg/d lower dose cytokin releas
syndrom peripher neuropathi pn relev drug administr
infect seriou advers event ae difficult determin caus
drug continu administr permacath infect baselin
diseas progress therefor concern studi
see figur seriou immun reaction caus life-threaten low blood
pressur short breath tachycardia requir hospit note
common ae car-t therapi trial patient experienc
grade compar grade grade fortun grade
typic manag support care usual requir intervent infus
interrupt necessarili requir porter et al howev grade quit
seriou usual requir hospit patient experienc grade
receiv mcg/d state mcg/d dose toler due
pn event grade central nervou system toxic report
pn less seriou toxic appear pn mitig
lower dose next trial help determin optim dose
mcg/d maximum toler dose balanc ae vs efficaci feel
drug show decent safeti exclud mcg/d dose known caus
immune-bas therapi car-t new treatment evolv steroid
tocilizumab hope better strategi develop gain experi
figur safeti mcg/d toler dose
bite target relapsed/refractori aml
data present less conclus
efficaci believ less predict dose
respons initi data present see modest relationship
higher dose stronger respons see figur
clinicaltri gov entri three patient mcg/d group show complet
remiss cr compar one patient mcg/d howev surpris see
mfl mrl less optim respons vs cr would like see
mcg/d even mcg/d achiev mfr less predict respons could due
ae result trial failur tf ae better control might
abl see predict dose-depend respons futur trial view
initi efficaci data point possibl success still work
need optim predict efficaci data would give us
figur dose vs respons
remiss incomplet count recoveri mlf morpholog leukemia-fre state
charl martineau univers toronto highli refractori patient similar baselin charact demonstr
trial popul advanc see figur base number alon
appear patient less advanc although aml
explos diseas patient progress quickli mm median diseas
durat year vs year
prior line therapi median rang
bone marrow blast baselin median rang
pose potenti safeti concern need address subsequ trial
surpris potenti problem trial similar
note common ae immunotherapi appear
less predict respons grade episod occur low-dos
group mcg/d figur would expect higher dose display
correspond higher grade hope abl better control
futur trial display predict relationship note compani
activ work protocol control includ potenti administr
tocilizumab therapi use prevent treat patient receiv car-t
figur safetycr common ae
ae note
overal less convinc data
earli evid activ sick patient compani work mitig
ae protocol could includ step-up dose corticosteroid pretreat
iv fluid tocilizumab potenti drug interrupt dose perspect
use two-step approach help optim dose clinic respons
bridg cell cancer cell bispecif cell engag bite monoclon
antibodi use link cell cancer cell increas abil patient
immun system kill cancer cell cancer cell notori evad detect
person immun system allow cancer cell prolifer uncontrol
monoclon antibodi use mani year target cancer cell remov
develop bispecif intend build upon success singl
monoclon antibodi differ bispecif two antigen bind site
versu one singl monoclon antibodi one piec bind receptor
activ cytotox lymphocyt target specif antigen tumor cell
bcma etc purport advantag bispecif includ
improv bind specif dual specif allow precis
bind help cell recogn bind mhc-present antigen target
cell also two bind site help limit unintent bind target
reduc side effect
decreas need antigen process bite design
function replac mhc ipeptidet cell receptor complex bite
bind cell complex select converg cancer cell tumor
cell activ mediat direct lysi cancer cell see figur
figur engag endogen cell target cancer cell
increas t-cell activ bind target site connect
cytotox t-cell tumor cell activ t-cell promot tumor cell
improv abil adapt multipl structur conform
separ single-chain monoclon ab held togeth flexibl peptid linker
permit bind greater number structur conform see figur
help improv abil bite link tumor cell
figur adapt multipl conform
chemotherapi requir prior treatment state
lympho-deplet chemotherapi would necessari prior administr
bispecif contrast car-t therapi patient
commonli given chemo deplet endogen lymphocyt reduc
immunosuppress cell may threaten car-t prolifer pretreat
could help patient keep immun system fight infect
believ bcma high-valu target market multipl myeloma
estim within next six year includ novel cell-therapi target
bcma meanwhil competit fierc anti-bcma immunotherapi see figur
take smaller piec market highlight mm remain challeng
sever trial failur recent gilead anti-bcma car-t scrap
owe lack efficaci compani believ efficaci profil
compar advanc cell therapi asset howev see promis data
celgen jacarh two cell therapi target bcma still
data earli matter asset celgen decid move forward
manufactur administr constraint like remain
figur anti-bcma immunotherapi clinic develop
extend half-lif bite step develop one main
critic short half-liv asset bodi patient
must infus via continu iv infus inconveni put
immunocompromis patient greater risk infect due perman cathet
result two phase bite seek reduc
infus time ideal could singl weekli infus one drawback long-
act formul manag advers event continu
infus pump turn immedi side effect occur data
expect exact time disclos yet state data
could possibl releas
beyond vari prolif oncolog pipelin bite
small molecul cell therapi oncolyt viru next month
also expect updat recent encourag pre-clin data
present american associ cancer research meet atlanta
addit interest oncolog asset upcom data
follow novel oncolog asset set present data
kra inhibitor solid tumor follow compel preclin
data expect initi clinic data june kra tradit
difficult target due high mutat rate oncogen upstream target
egfr tki success inhibit kra due mutat
therefor novel drug like target mutat kra kra
mutat present lung adenocarcinoma solid
tumor interest see data show success even modest
efficaci could big upsid owe lack success therapi larg market
size first clinic target link clinic trial
inhibitor mm aml suggest
asset could addit synergist inhibitor
iv formul oral
overal optimist need data increas convict amgen
bite data demonstr hint toward efficaci mix side
effect data encourag larger trial need confirm efficaci
due low number respond howev see efficaci patient
advanc diseas good news specif trail felt display
predict dose-respons vs efficaci may limit
effici dose could potenti limit ae data less promis
lower number respond less predict dose-depend respons
seriou issu trial need mitig futur trial interestingli
potenti could import half-lif extend
infus pump turn limit drug addit
central neurotox could potenti problem sinc common longer
half-lif drug overal optimist need see clinic data
drug perform rel asset develop
forecast incom statement balanc sheet statement cash flow
project fy revenu forecast
non-gaap ep figur incom
statement balanc sheet found figur statement cash flow
found figur
aimovig royalti novarti ex-u sale
product revenu
product revenu
product revenu
product revenu
weight average share use calcul dilut ep
cash equival
properti equip net
intang asset sbc
accru expens
commit conting
accumul comprehens loss
figur amgen statement flow
statement flow
chang asset liabil
net cash use oper activ
purchas market secur
proce sale market secur
net cash use invest activ
net proce issuanc debt
repurchas common stock
repay debt oblig
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
holt view
run project holt valuat framework result
per share slightli target price
holt credit suiss proprietari methodolog compani analysi stock
select deliv object global consist view compani
holt use perform metric known return invest cfroi
adjust account distort compar econom perform across
sector region time appl appl basi holt valuat methodolog
base discount cash flow framework number distinguish featur
includ uniqu way calcul termin valu firm cost capit
base forecast holt dcf get warrant valuat per
share slightli target price due inclus long term
liabil holt debt deduct ev get equiti valu mainli
compris liabil repatri tax
beyond holt dcf framework appli mean revers methodolog
calcul termin valu assum cfroi discount rate fade gradual
long term averag asset growth fade reach averag growth
also run sensit analysi show valuat
sensit top line growth indic get target price holt impli
long term sale growth
charl martineau univers toronto figur holt analysi
cs peer relationship amgen
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag figur
figur cs peer relationship map
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
robert bradway chairman ceo
mr bradway serv director compani sinc chairman
board director sinc prior presid sinc
chief execut offic sinc serv compani
presid chief oper offic mr bradway join compani vice
presid oper strategi serv execut vice presid chief financi
offic prior join compani manag director
morgan stanley london begin respons firm
bank depart corpor financ activ europ mr bradway
director boe compani aerospac compani manufactur commerci
airplan defens space secur system sinc
director norfolk southern corpor transport compani
david melin execut vice presid chief offic
mr melin becam execut vice presid chief financi offic
serv senior vice presid chief financi offic compani
serv vice presid corpor control chief
account offic prior serv varieti senior leadership role
gener motor compani year last posit vice presid
chief financi offic north america mr melin director abb ltd global
industri technolog compani base switzerland sinc current serv
chairman financ audit complianc committe also director trw
automot hold corp supplier automot system modul compon
acquisit zf friedrichshafen ag
david rees execut vice presid research develop
dr rees becam execut vice presid research develop join
compani held leadership role develop medic scienc
discoveri research dr rees senior vice presid translat scienc
oncolog senior vice presid translat scienc
prior join director clinic research breast cancer
intern research group co-found presid chief
medic offic translat oncolog research intern not-for-profit academ
clinic research organ dr rees previous serv faculti
univers california lo angel univers california san francisco
mr gordon becam execut vice presid global commerci oper prior
join compani chief commerci offic bristol-my squibb
compani bm juli mr gordon serv head world-wide
market bm prior serv varieti leadership role
bm year
jonathan senior vice presid gener counsel secretari
mr graham becam senior vice presid gener counsel secretari
senior vice presid gener counsel danah corpor
mr graham vice presid litig legal polici gener
electr compani ge prior ge partner connolli llp
ms johnston becam senior vice presid human resourc
execut vice presid chief administr offic celanes
corpor ms johnston serv seri progress
leadership role last posit vice presid human resourc
prior join compani held human resourc posit inc
cynthia patton senior vice presid chief complianc offic
ms patton becam senior vice presid chief complianc offic join
compani ms patton associ gener counsel
ms patton vice presid law previous serv senior
vice presid gener counsel secretari scan health
mr piacquad becam senior vice presid busi develop join
compani serv vice presid strategi corpor develop
mr piacquad serv vice presid busi develop
princip david piacquad consult llc
serv senior vice presid busi develop licens schering-plough
corpor schering-plough prior schering-plough serv seri
leadership role financ busi develop last posit
vice presid ventur busi develop
mr santo becam execut vice presid oper join compani
execut director manufactur technolog mr santo
held number vice presid role compani engin manufactur site
oper drug product senior vice presid
manufactur prior join compani serv site gener manag js
cordi oper puerto rico prior held sever manag posit
industri transport busi
compani mention price
